Clinical trial

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

NCT01308567

Study summary

ClinicalTrials.gov

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Cabazitaxel (XRP6258) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Docetaxel (XRP6976) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisone View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-05-05

PhasePHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Cabazitaxel (XRP6258)DRUG

Docetaxel (XRP6976)DRUG

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Sanofilead sponsor

Mapped research locations

LimaPeru4 BarcelonaSpain3 ParisFrance3 ShanghaiChina3 BostonMassachusetts, United States2 MadridSpain2 BucharestRomania2 LisbonPortugal2 KyivUkraine2 PortoPortugal2 Cluj-NapocaRomania2 Porto AlegreBrazil2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01308567 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.